Hypertension

The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812


NOVEMBER 26, 2015

VOL. 373 NO. 22

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

The SPRINT Research Group*





Discontinued intervention refers to participants who discontinued the study treatment but did not withdraw consent or become lost to follow-up.




Figure 2. Systolic Blood Pressure in the Two Treatment Groups over the Course of the Trial.

The systolic blood-pressure target in the intensive-treatment group was less than 120 mm Hg, and the target in the standard-treatment group was less than 140 mm Hg. The mean number of medications is the number of blood-pressure medications administered at the exit of each visit. I bars represent 95% confidence intervals.




Figure 3. Primary Outcome and Death from Any Cause.

Shown are the cumulative hazards for the primary outcome (a composite of myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes) (Panel A) and for death from any cause (Panel B). The inset in each panel shows the same data on an enlarged y axis. CI denotes confidence interval.

Table 2. Primary and Secondary Outcomes and Renal Outcomes.*

Outcome	Intensive Tre	eatment	Standard Tre	eatment	Hazard Ratio (95% Cl)	P Value
	no. of patients (%)	% per year	no. of patients (%)	% per year		
All participants	(N=46)	78)	(N=468	33)		
Primary outcome†	243 (5.2)	1.65	319 (6.8)	2.19	0.75 (0.64–0.89)	<0.001
Secondary outcomes						
Myocardial infarction	97 (2.1)	0.65	116 (2.5)	0.78	0.83 (0.64–1.09)	0.19
Acute coronary syndrome	40 (0.9)	0.27	40 (0.9)	0.27	1.00 (0.64–1.55)	0.99
Stroke	62 (1.3)	0.41	70 (1.5)	0.47	0.89 (0.63–1.25)	0.50
Heart failure	62 (1.3)	0.41	100 (2.1)	0.67	0.62 (0.45–0.84)	0.002
Death from cardiovascular causes	37 (0.8)	0.25	65 (1.4)	0.43	0.57 (0.38–0.85)	0.005
Death from any cause	155 (3.3)	1.03	210 (4.5)	1.40	0.73 (0.60–0.90)	0.003
Primary outcome or death	332 (7.1)	2.25	423 (9.0)	2.90	0.78 (0.67–0.90)	<0.001
Participants with CKD at baseline	(N=1330)		(N=1316)			
Composite renal outcome <u>‡</u>	14 (1.1)	0.33	15 (1.1)	0.36	0.89 (0.42–1.87)	0.76
≥50% reduction in estimated GFR§	10 (0.8)	0.23	11 (0.8)	0.26	0.87 (0.36–2.07)	0.75
Long-term dialysis	6 (0.5)	0.14	10 (0.8)	0.24	0.57 (0.19–1.54)	0.27
Kidney transplantation	0		0			
Incident albuminuria¶	49/526 (9.3)	3.02	59/500 (11.8)	3.90	0.72 (0.48–1.07)	0.11
Participants without CKD at baseline	(N = 33	32)	(N = 334	45)		
≥30% reduction in estimated GFR to <60 ml/ min/1.73 m ² §	127 (3.8)	1.21	37 (1.1)	0.35	3.49 (2.44–5.10)	<0.001
Incident albuminuria¶	110/1769 (6.2)	2.00	135/1831 (7.4)	2.41	0.81 (0.63–1.04)	0.10

ORIGINAL ARTICLE

Final Report of a Trial of Intensive versus Standard Blood-Pressure Control

Subgroup	Intensive	Standard	Hazard Ratio (9	5% CI)	P Value
	no. of participa	nts/total no. (%)			
Overall	264/4678 (5.6)	354/4683 (7.6)		0.73 (0.63-0.86)	
Previous chronic kidney disease					0.23
No	146/3349 (4.4)	218/3367 (6.5)	B	0.67 (0.54-0.82)	
Yes	118/1329 (8.9)	136/1316 (10.3)		0.82 (0.63-1.05)	
Age					0.24
<75 yr	156/3361 (4.6)	196/3364 (5.8)		0.79 (0.64-0.97)	
≥75 yr	108/1317 (8.2)	158/1319 (12.0)	— —	0.65 (0.50-0.83)	
Sex					0.42
Female	85/1684 (5.0)	101/1648 (6.1)		0.82 (0.61-1.09)	
Male	179/2994 (6.0)	253/3035 (8.3)	— — —	0.70 (0.58-0.85)	
Race					0.72
Black	70/1454 (4.8)	96/1493 (6.4)		0.77 (0.56-1.05)	
Non-Black	194/3224 (6.0)	258/3190 (8.1)		0.72 (0.59-0.86)	
Previous cardiovascular disease					0.46
No	161/3738 (4.3)	229/3746 (6.1)		0.70 (0.57-0.86)	
Yes	103/940 (11.0)	125/937 (13.3)		0.80 (0.61-1.04)	
Systolic blood pressure					0.64
≤132	77/1583 (4.9)	109/1553 (7.0)	←∎──	0.67 (0.50-0.90)	
133–144	85/1489 (5.7)	120/1549 (7.7)		0.74 (0.56-0.98)	
≥145	102/1606 (6.4)	125/1581 (7.9)		0.82 (0.63-1.07)	
			0.5 0.75 1.0 1.2		

The SPRINT Research Group*

- Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group.
- Targeting a systolic BP <120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic BP<140 mm Hg, both during receipt of the randomly assigned therapy and after the trial.

Figure 2. Subgroup Analysis of Hazard Ratios for the Primary Outcome during the Intervention Period (through August 20, 2015).

The box sizes are proportional to the precision of the estimates, with larger boxes indicating a greater degree of precision. The subgroup of participants with no previous chronic kidney disease includes some participants with unknown status with respect to chronic kidney disease at baseline. Black race includes Hispanic Black and Black as part of a multiracial identification. P values were adjusted for multiple subgroups tested.

Current Guidelines

- 2016 National Heart Foundation (Australia)
 - Initiate drug treatment in patients with low-CVD risk (<10%; 5-year risk) with persistent BP ≥160/100 mmHg
 - Initiate drug treatment in patients with moderate-CVD risk (10-15%; 5-year risk) with persistent SBP ≥140 and/or DBP ≥90 mmHg
 - Treatment target is <140/90mmHg in uncomplicated hypertension. This also includes those with a history of chronic kidney disease, peripheral vascular disease, stroke, and diabetes mellitus
 - In selected high-CVD risk (>15%; 5-year risk) populations a secondary target of <120 mmHg systolic can be considered (but require close follow-up)
 - For elderly individuals of ≥75 years, no specific threshold for commencing treatment is provided, but the primary recommended systolic target is <120 mmHg

Current Guidelines

- 2017 American College of Cardiology/American Heart Association
 - clinic systolic BP target of <130 mm Hg for uncomplicated hypertension (unless with low-CVD risk, where the target was ≤140 mmHg) and for noninstitutionalized, ambulatory, community-dwelling adults aged ≥65 years
- 2018 European Society of Cardiology/European Society of Hypertension
 - <65 years of age: clinic systolic BP target of <130 mm Hg for uncomplicated hypertension
 - ≥65 years:
 - Threshold for treatment: SBP 140mmHg (65-80 years), 160mmHg (>80 years)
 - Target for treatment is SBP <140mmHg

BP Measuring Methods

Table 4.3 Criteria for diagnosis of hypertension using different methods of blood pressure measurement

Method of measurement	Systolic (mmHg)		Diastolic (mmHg)
Clinic blood pressure	≥140	and/ or	≥90
ABPM daytime (awake)	≥135	and/ or	≥85
ABPM night-time (asleep)	≥120	and/ or	≥70
ABPM over 24 hours	≥130	and/ or	≥80
HBPM	≥135	and/ or	≥85

Ambulatory bl	ood pressure :	report			
Patient name:	N	/Ir J Bond	ID:		007
Scan start date	2	9/08/2011	Clinic SBP	/DBP	140/90 ┥
Scan start time	. 1	2:08	Total readi	ings	56
Scan end date	3	0/08/2011	Successful	l readings	52
Scan end time	1	3:37	Percent su	Iccessful	93 🔫
180 - (6) umu 160 - 140 - 140 - 120 - 000 - 80 - 60			Night Asleep	Awake	
Summary	200 1500	1800 2100	0000 0300	0600 0900	1200 Time
Summary	Min	Mean	Max	STD	BP load (<20%)
Systolic	125	151 -	183	13.4	94%
Diastolic	71	90	105	11.9	67%
Heart rate	54	70	94	9.5	
Day summary					
	Min	Mean	Max	STD	BP load
Systolic	125	152	176	12.2	91%
Diastolic	73	91	111	10.9	68%
Heart rate	54	71	90	8.7	
Night summa	ry 22:00 to 6	6:00			
	Min	Mean	Max	STD	BP load
Systolic	129	146	183	14.7	100%
Diastolic	71	86	115	135	70%
Heart rate	57	69	94	11.1	
% Night SBP dip	o (>10%)	3.9%	% Night DI	3P dip (>10%)	5.5% ┥
Awake summ	ary 7:00 to 1	1:30			
	Min	Mean	Max	STD	BP load
Systolic	132	155	183	11	93%
Diastolic	75	92	115	11	68%
Heart rate	55	73	94	9	
Asleep summ	-		Merry	CITE	
Crustelia	Min	Mean	Max	STD	BP Load
Systolic	125 71	134	143 85	5	100% 55%
Diastolic Heart rate	71 54	76 60	85 67	5	00%
% Night SBP di				ь BP dip (>10%)	28% 🚽
Interpretation: hypertension g (<10%) this is of values are satis	Patient ABP rade 1 thresho lue to very late sfactory (>10%	day, night, awake old (shown in red) e sleep onset. The	e, asleep BP, BP). While night su	load values are a ummary suggests	ll above s 'nondipping'
Recommendati	ion: Commenc			herapy. Assess c	ardiovascular risk





Name:

Start date:

When to take home BP?

- DO take measures at around the same time in the morning and evening
- DO take before taking medication, food or vigorous exercise
- DO take for 7 days (5 day minimum)
- DO take as advised by your doctor e.g. before visiting the doctor or after medication change

How to take home BP?

- DO sit quietly for 5 minutes (no talking/distractions such as TV/extreme temperatures)
- DO sit with feet flat on floor, legs uncrossed, upper arm bare, back and arm supported (relaxed position with the cuff at heart level)
- DO take two measures 1 minute apart
- DO record each measure in a paper diary or an electronic spread sheet
- DO take a copy of the BP readings to your doctor appointment
- DO NOT smoke or drink caffeine 30 minutes before measuring BP
- DO NOT measure your BP if uncomfortable, stressed or in pain

	Da	i y 1	Da	ay 2	Da	у З	Da	ay 4	Da	y 5	Da	y 6	Da	ay 7
	Morning	Evening	Morning	Evening	Morning	Evening	Morning	Evening	Morning	Evening	Morning	Evening	Morning	Evening
SBP 1														
DBP 1														
SBP 2														

Average BP (except day 1)

SBP DBF

Medications (name and dose):

DBP 2

Other BP readings as requested by your doctor (e.g. standing or midday or when you are symptomatic i.e. dizzy/headache):

Masked Hypertension

Patterns of Blood pressure





Table 2. Prevalence of Masked Hypertension by Treatment Status in Diabetics and Nondiabetics

	Prevalen	ce, %		Odds Ratio	
Treatment Status	Nondiabetics	Diabetics	Unadjusted	Partly Adjusted	Fully Adjusted
Untreated	18.8% (1031/5486)	29.3% (67/229)	1.79 (1.33–2.40); <i>P</i> <0.001	1.46 (1.08–1.98); <i>P</i> =0.014	1.35 (0.98–1.86); <i>P</i> =0.065
Treated	30.5% (192/630)	42.5% (37/87)	1.69 (1.07–2.67); <i>P</i> =0.025	1.59 (1.00–2.52); <i>P</i> =0.051	1.59 (0.98–2.58); <i>P</i> =0.058

Hypertension. 2015;65:16-20.

Two-Drug Combinations as First-Step Antihypertensive Treatment

Giuseppe Mancia, Federico Rea, Giovanni Corrao, Guido Grassi




ratio; and OR, odds ratio. From Corrao et al42 and Rea et al.48,59

cidence risk

Circ Res. 2019;124:1113-1123

Two-Drug Combinations as First-Step Antihypertensive Treatment

Giuseppe Mancia, Federico Rea, Giovanni Corrao, Guido Grassi



- Initial monotherapy preferred in:
 - Patients with grade 1 hypertension whose baseline SBP is closer to 140mmHg
 - Elderly and frail patients